Latest News

11/09 Taiwan BIO Weekly

2026-11-09
 
Taiwan BIO Weekly
Acepodia Biotechnologies Doses First Patient in Liver Cancer Clinical Trial
5 November, 2026
Acepodia Biotechnologies (TW: 6976) announced first patient dosing in its Phase I clinical trial of ACE723 in China. Developed using its proprietary Antibody-Dual-Drugs Conjugation (AD2C) platform, ACE723 targets GPC3 to treat unresectable or metastatic hepatocellular carcinoma (HCC). This milestone marks the AD2C platform's transition from preclinical development to human trials. More... (in Chinese)
 
CPHI Milan 2026: "Team Taiwan" Bridges Global Pharma Supply Chain with Cross-Sector Capabilities
4 November, 2026
On the second day of CPHI Milan 2026 (October 7), the "Taiwan-Europe Pharmaceutical Industry Trends Forum & Business Matching Event" organized by the Industrial Technology Research Institute (ITRI) took place at Fiera Milano, following the previous day's grand opening of the "Taiwan Pharma Pavilion" and participation in the CPHI Leadership Summit. More...
 
Taiwan's iXensor Raises NT$50 Million in Second Rights Offering, Led by Center Laboratories, Targets Single-Month Profitability
4 November, 2026
Taiwan's iXensor (TW: 6734) has completed its second cash capital increase of the year, issuing 10,000 new shares at NT$5 each to raise NT$50 million (approximately US$1.5 million), with all funds now received. Center Laboratories led the subscriber portion. More...
 
Medeon Biodesign Secures Taiwan Approval for Minimally Invasive BPH Device
4 November, 2026
Medeon Biodesign (TW: 6499) announced that its minimally invasive Urocross Expander System, for treating benign prostatic hyperplasia (BPH), has received Taiwan FDA marketing approval, following US FDA 510(k) clearance in March 2026 and its first commercial use in the US in October. The company plans to expand commercialization in Taiwan and the US while pursuing international licensing opportunities. BPH affects approximately 50% of men aged 60 and 70-80% of those over 70, with more than 800,000 people seeking treatment in Taiwan in 2025. More... (in Chinese)
 
PharmaEssentia's Ropeg Expands Global ET Approvals While Europe Awaits Regulatory Clearance
Press release
3 November, 2026
PharmaEssentia's (TW: 6446) blood cancer treatment, ropeginterferon alfa-2b (Ropeg), has secured approvals for essential thrombocythemia (ET) in Taiwan, Japan, the United States, and China, widening treatment options for patients with the chronic disease. In Europe, however, the ET indication remains unapproved, underscoring the gap between clinical advances and patient access across global markets. More...
 
Ever Fortune.AI's Large Vessel Occlusion Detection System Receives US FDA Clearance
3 November, 2026
Ever Fortune.AI (TW: 6841) announced on November 2 that its Large Vessel Occlusion (LVO) Detection System has received US FDA 510(k) clearance, marking the company's 16th FDA clearance. The new system further expands its AI-based solutions for acute and critical brain conditions. Using deep learning to automatically analyze CT angiography images, the system identifies suspected LVOs and sends alerts through hospital picture archiving and communication systems (PACS) and radiology information systems (RIS), helping medical teams prioritize high-risk cases. More... (in Chinese)
 
TWi Biotechnology Targets 2027 US and EU Regulatory Filings for AC-203
2 November, 2026
TWi Biotechnology (TW: 6610) reported new progress in subgroup analyses of AC-203, its investigational treatment for epidermolysis bullosa simplex (EBS), despite the drug failing to meet the primary efficacy endpoint in its Phase II/III clinical trial. The company plans to consult with US and European regulatory authorities in the first quarter of 2027, seeking to avoid the need for additional clinical trials. It aims to submit regulatory applications as early as the second half of 2027, with approval targeted for 2028. More... (in Chinese)
 
TAHO Pharmaceuticals Expands Pediatric Indications for Its Antiemetic Oral Dissolving Film
2 November, 2026
TAHO Pharmaceuticals (TW: 6467) announced on November 1 that its chemotherapy-induced nausea and vomiting treatment TAH4411, already marketed in Japan, has completed a Phase III trial for a new indication targeting vomiting associated with acute gastroenteritis in children. Japanese partner Miyarisan Pharmaceutical has submitted a marketing authorization application to Japan's regulatory authorities. More... (in Chinese)
 
HanchorBio's HCB303 Receives US and Taiwan Regulatory Clearance, Set to Begin Multinational Phase I Trial
2 November, 2026
HanchorBio (TW: 7827) announced on November 1 that its trispecific fusion protein candidate HCB303 has received clinical trial approval from both the US FDA and the Taiwan TFDA, clearing the way for a multinational Phase I trial in both countries. Developed using the company's proprietary FBDB platform, HCB303 targets advanced, relapsed or refractory solid tumors and combines a number of immune regulatory mechanisms to activate antitumor responses involving T cells, natural killer (NK) cells and macrophages. More... (in Chinese)
 
LigamiX Hybrid Regenerative Ligament Technology: From Cross-Disciplinary Breakthrough to Advanced Medtech Commercialization
1 November, 2026
Anterior cruciate ligament (ACL) tears are commonly treated with autografts or artificial ligament reconstruction. Autografts require harvesting the patient's own tissue, while artificial ligaments face challenges in integrating synthetic materials with human tissue. More...
 
Taiwan hospital develops experimental treatment for lung fibrosis
30 October, 2026
Taichung-based China Medical University Hospital said Thursday it developed a device that mimics breathing to train stem cells to produce vesicles for the potential treatment of pulmonary fibrosis. More...
 
Taiwan's Anxo broadens pharmaceutical portfolio
30 October, 2026
Anxo Pharmaceutical Co. (TW: 6677) has expanded its drug portfolio, securing approval for a smoking cessation drug and exclusive distribution rights for a melatonin product in Taiwan, CTEE reported Friday. More...
 
=========================================
Please note that Taiwan BIO is not responsible for the accuracy of third-party news stories covered in this newsletter.
=========================================
Taiwan Bio Industry Organization (Taiwan BIO)

Tel: +886 2 27836028 Fax: +886 2 27836027
Email: biotaiwan@gmail.com
BIO Asia-Taiwan 2027 (27-31 July, 2027)
=========================================
Taiwan Bio Industry Organization (Taiwan BIO)
Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd.,
Nangang Dist., Taipei, Taiwan (11571)
=========================================